The tweet was deleted by the author.
But we saved everything 🙂.
Biomea Fusion has presented new data from the Phase II COVALENT-112 study at the 86th Scientific Sessions of the American Diabetes Association, focusing on icovamenib in people with type 1 diabetes.
The data, delivered by Dr. Juan Pablo Frías, suggest that icovamenib may offer promising new treatment avenues for patients. The study is part of Biomea Fusion's ongoing efforts to advance novel therapies for diabetes and metabolic disorders. Further details on efficacy and safety outcomes are awaited as the research progresses.
Biomea Fusion recently reported promising Phase II COVALENT-112 data supporting ico as a potential first-in-class therapy option for type 1 diabetes, according to a prior update from the company. Earlier this year, Biomea Fusion also engaged with global industry leaders to explore new collaboration opportunities at the BIO International Convention held in June. These activities reflect the company’s continued focus on advancing therapies for diabetes and metabolic disorders.